Nanjing Vazyme Biotech Co.Ltd(688105) announced on March 13 that its wholly-owned subsidiary Nanjing Vazyme Biotech Co.Ltd(688105) medical obtained the medical device registration change document (in vitro diagnostic reagent) approved by the State Food and Drug Administration on March 12 The New Coronavirus antigen detection kit produced by Nanjing Vazyme Biotech Co.Ltd(688105) has completed the intended use of medical device product registration, increased the sample type and the changes in the content of the instructions.
Nanjing Vazyme Biotech Co.Ltd(688105) said that the above changes further responded to the national covid-19 epidemic prevention and detection policy and helped to further enhance the company’s competitiveness in relevant fields. However, the actual sales situation of the above New Coronavirus antigen detection products is affected by many factors such as COVID-19 epidemic situation, prevention and control policy and testing demand. Nanjing Vazyme Biotech Co.Ltd(688105) is not yet able to predict the specific impact of the product’s sales on future performance.
